Capricor Therapeutics Treats Six Coronavirus Patients with Proprietary CAP-1002 and Nobody Dies; Stock Rallies 300% Following a Company Press Release Trumpeting 100% Survival Rate



“New data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases”

So only 6 people were treated….

“Over the course of one month, six critically ill COVID-19 patients”…Read more

https://archive.is/fCIDi

Leave a Reply

%d bloggers like this: